EUVIMEDEUVIMED entdecken
Crossref

A Review: Gene Therapy for Inherited Retinal Diseases: Clinical Advances, Regulatory Milestones, and Emerging Therapeutic Frontiers

Mirza Mohammed Ismail Baig, Qiu Aowang, Sun Ruxu, Wang Ningyu, Jiao Ziyun, Zhu Ziyu, Jassim Subair, Zhang Weiwei

IFR Journal of Medicine and Surgery · 18.07.2025 · 2 (3) · 30-38

DOI: 10.70146/msv02i03.005 ↗

Kurz gefasst

Fachartikel in der Zeitschrift IFR Journal of Medicine and Surgery, erschienen am 18.07.2025. Verfasst von Mirza Mohammed Ismail Baig und 7 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Inherited retinal diseases (IRDs) are a genetically heterogeneous group of progressive disorders and a leading cause of visual impairment worldwide. Advances in molecular genetics and vector engineering have enabled the development of targeted gene therapies, culminating in the clinical approval of voretigene neparvovec-rzyl for RPE65-associated retinal dystrophy.

Methods

This review critically evaluates published literature and clinical trial data on gene therapy approaches for IRDs, including gene augmentation, genome editing, and RNA-based modulation. Delivery strategies, vector platforms, regulatory frameworks, and ethical implications are also examined to provide a comprehensive overview of the current landscape and future directions.

Results

Approved and investigational therapies demonstrate encouraging outcomes in restoring or stabilizing visual function across a spectrum of IRDs. The clinical pipeline includes AAV-based therapies targeting RPGR, CHM, and RS1, with evolving approaches such as dual-vector delivery, CRISPR/Cas9 gene editing, and antisense oligonucleotide therapy. Challenges related to immunogenicity, vector capacity, manufacturing scale-up, and equitable access remain prominent.

Conclusion

Gene therapy for IRDs has entered a pivotal phase of clinical translation. While technological innovation continues to broaden therapeutic reach, long-term success will depend on overcoming logistical, regulatory, and ethical barriers. Future efforts should emphasize scalable delivery, global accessibility, and mutation-specific personalization to achieve meaningful impact in patient care.

Zitieren

APA

Baig, M. M. I., Aowang, Q., Ruxu, S., Ningyu, W., Ziyun, J., Ziyu, Z., Subair, J., & Weiwei, Z. (2025). A Review: Gene Therapy for Inherited Retinal Diseases: Clinical Advances, Regulatory Milestones, and Emerging Therapeutic Frontiers. IFR Journal of Medicine and Surgery, 2(3), 30-38. https://doi.org/10.70146/msv02i03.005

Vancouver

Baig MMI, Aowang Q, Ruxu S, Ningyu W, Ziyun J, Ziyu Z, et al. A Review: Gene Therapy for Inherited Retinal Diseases: Clinical Advances, Regulatory Milestones, and Emerging Therapeutic Frontiers. IFR Journal of Medicine and Surgery. 2025;2(3):30-38. doi:10.70146/msv02i03.005

BibTeX
@article{Baig2025,
  author = {Baig, Mirza Mohammed Ismail and Aowang, Qiu and Ruxu, Sun and Ningyu, Wang and Ziyun, Jiao and Ziyu, Zhu and Subair, Jassim and Weiwei, Zhang},
  title = {A Review: Gene Therapy for Inherited Retinal Diseases: Clinical Advances, Regulatory Milestones, and Emerging Therapeutic Frontiers},
  journal = {IFR Journal of Medicine and Surgery},
  year = {2025},
  volume = {2},
  number = {3},
  pages = {30--38},
  doi = {10.70146/msv02i03.005}
}
Kostenlos starten →